A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Clinical trial NCT03003676 · COMPLETED
Trial details
- NCT number
- NCT03003676
- Sponsor
- Targovax Oy
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-01
- Primary completion
- 2020-07-01
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.